Newer Treatments for Advanced Hepatocellular Carcinoma

Overview

Journal Korean J Intern Med

Specialty General Medicine

Date 2014 Mar 21

PMID 24648795

Citations 12

Authors

Myeong Jun Song

Si Hyun Bae

Affiliations

Soon will be listed here.

Abstract

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. The only curative treatment modalities for HCC are surgery, percutaneous ablation, and liver transplantation. Unfortunately, the majority of patients have unresectable disease at diagnosis. Therefore, effective treatment options are needed for patients with advanced HCC. The current standard treatment for patients with advanced HCC, according to the Barcelona Clinic Liver Cancer staging system, is the multikinase inhibitor sorafenib. Other alternative therapies are required, due to the limited treatment response to, and tolerance of, this molecular target agent. Clinical trials of hepatic artery infusion chemotherapy, radioembolization, and multimodal treatments have shown favorable results in advanced HCC patients. This article introduces new treatment modalities for advanced HCC and discusses future therapeutic possibilities.

Citing Articles

Hesperetin and Capecitabine Abate 1,2 Dimethylhydrazine-Induced Colon Carcinogenesis in Wistar Rats via Suppressing Oxidative Stress and Enhancing Antioxidant, Anti-Inflammatory and Apoptotic Actions.

Hassan A, El-Kalaawy A, Abd El-Twab S, Alblihed M, Ahmed O Life (Basel). 2023; 13(4).

PMID: 37109513 PMC: 10146346. DOI: 10.3390/life13040984.

Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides.

Khan A, Wei X, Xu X J Hepatocell Carcinoma. 2021; 8:1089-1115.

PMID: 34522691 PMC: 8434852. DOI: 10.2147/JHC.S318070.

Determinants of pain in advanced HCC patients recieving hepatic artery infusion chemotherapy.

Wu Z, Guo W, Chen S, Zhuang W Invest New Drugs. 2020; 39(2):394-399.

PMID: 33006020 PMC: 7960585. DOI: 10.1007/s10637-020-01009-x.

Value of surgical resection compared to transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein tumor thrombus: A meta-analysis of hazard ratios from five observational studies.

Kang K, Song S, Chung C, Park Y Ann Hepatobiliary Pancreat Surg. 2020; 24(3):243-251.

PMID: 32843588 PMC: 7452806. DOI: 10.14701/ahbps.2020.24.3.243.

Transarterial Chemoembolization in Treatment-Naïve and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.

Kim D, Lim T, Jeon M, Kim B, Park J, Kim D Dig Dis Sci. 2019; 64(12):3660-3668.

PMID: 31187326 DOI: 10.1007/s10620-019-05701-8.

References

Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K . Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci. 2007; 99(1):159-65. PMC: 11158187. DOI: 10.1111/j.1349-7006.2007.00648.x. View

Sangro B, Inarrairaegui M, Bilbao J . Radioembolization for hepatocellular carcinoma. J Hepatol. 2011; 56(2):464-73. DOI: 10.1016/j.jhep.2011.07.012. View

Ganeshan A, Upponi S, Hon L, Warakaulle D, Uberoi R . Hepatic arterial infusion of chemotherapy: the role of diagnostic and interventional radiology. Ann Oncol. 2007; 19(5):847-51. DOI: 10.1093/annonc/mdm528. View

Woo H, Bae S, Park J, Han K, Chun H, Choi B . A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009; 65(2):373-82. DOI: 10.1007/s00280-009-1126-2. View

Park M, Kim S, Park J, Kim D, Ahn S, Han K . Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol. 2012; 71(1):165-73. DOI: 10.1007/s00280-012-1993-9. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

Yamasaki T, Sakaida I . Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res. 2011; 42(4):340-8. DOI: 10.1111/j.1872-034X.2011.00938.x. View

Lawrence T, Robertson J, Anscher M, Jirtle R, ENSMINGER W, Fajardo L . Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys. 1995; 31(5):1237-48. DOI: 10.1016/0360-3016(94)00418-K. View

Kim H, Kim J, Bae S, Park J, Han K, Woo H . A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol. 2011; 16(4):355-61. PMC: 3304604. DOI: 10.3350/kjhep.2010.16.4.355. View

10.

Seong J, Park H, Han K, Chon C, Chu S, Kim G . Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res. 2003; 27(1):30-35. DOI: 10.1016/s1386-6346(03)00162-1. View

11.

Kim D, Park B, Kim Y, Han K, Bum Cho S, Cho K . Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study. Am J Clin Oncol. 2013; 38(5):495-501. DOI: 10.1097/COC.0b013e3182a78dba. View

12.

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

13.

Omata M, Lesmana L, Tateishi R, Chen P, Lin S, Yoshida H . Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4(2):439-74. PMC: 2900561. DOI: 10.1007/s12072-010-9165-7. View

14.

Wilhelm S, Adnane L, Newell P, Villanueva A, Llovet J, Lynch M . Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008; 7(10):3129-40. DOI: 10.1158/1535-7163.MCT-08-0013. View

15.

Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A . Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. J Nucl Med. 2010; 51(9):1377-85. DOI: 10.2967/jnumed.110.075861. View

16.

Kim B, Park J, Choi H, Kim D, Ahn S, Kim J . Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2010; 137(4):659-67. DOI: 10.1007/s00432-010-0917-5. View

17.

Kulik L, Carr B, Mulcahy M, Lewandowski R, Atassi B, Ryu R . Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2007; 47(1):71-81. DOI: 10.1002/hep.21980. View

18.

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

19.

Kennedy A, Nag S, Salem R, Murthy R, McEwan A, Nutting C . Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007; 68(1):13-23. DOI: 10.1016/j.ijrobp.2006.11.060. View

20.

Nishiyama M, Yamamoto W, Park J, Okamoto R, Hanaoka H, Takano H . Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res. 1999; 5(9):2620-8. View